TherapeuticsMD, Inc. (TXMD) stock
TXMDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 12/3029% below fair value
$1.91+0.10 (+5.52%)
Close on Nov 17, 2026Market cap $22.11MP/E –Yield –
TherapeuticsMD pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
TherapeuticsMD's pe ratio was 101.5× on Jul 31, 2026, against 0.2× a year earlier.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Jul 31, 2026 | 101.5× | +20.0 |
| 2025 | Dec 31, 2025 | 81.5× | +81.1 |
| 2024 | Jan 31, 2024 | 0.4× | +0.0 |
| 2023 | Dec 29, 2023 | 0.4× | – |
See a number that looks wrong?